SCHEMBL6773783

SCHEMBL6773783

CCOC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)c1cccc(NC(=O)NCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.52
ITGB3 P05106 4/20 0.51
ITGAV P06756 4/20 0.51
MAPT P10636 4/20 0.50
ATM Q13315 2/20 0.50
THRB P10828 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
TP53 P04637 2/20 0.48
EPHX2 P34913 1/20 0.48
PPARG P37231 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7824027 0.94 GPR139 (0.48) NAMPTITGB3ITGAVMAPTATM
SCHEMBL7832444 0.93 NAMPT (0.48) NAMPTITGB3ITGAVMAPTATM
SCHEMBL6779491 0.92 TSHR (0.55) NAMPTMAPTL3MBTL1LMNA
SCHEMBL6778765 0.89 HSD17B10 (0.55) NAMPTLMNAMAPK1
SCHEMBL6776731 0.89 NAMPT (0.49) NAMPTITGB3ITGAVMAPTTHRB
SCHEMBL7833496 0.88 ITGB3 (0.58) ITGB3ITGAVL3MBTL1LMNAMAPK1
SCHEMBL7836894 0.87 NAMPT (0.59) NAMPTL3MBTL1LMNA
SCHEMBL6778759 0.87 TP53 (0.48) MAPTLMNATP53ALDH1A1CA12
SCHEMBL7837655 0.85 NAMPT (0.59) NAMPT
SCHEMBL7835626 0.85 TSHR (0.48) NAMPTMAPTL3MBTL1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed